Entero Therapeutics (NASDAQ:GRDX) Rating Lowered to “Strong Sell” at Wall Street Zen

Entero Therapeutics (NASDAQ:GRDX) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “strong sell” rating in a note issued to investors on Saturday.

Entero Therapeutics Stock Performance

Entero Therapeutics stock opened at $3.96 on Friday. The company has a market capitalization of $28.23 million, a PE ratio of -2.08 and a beta of 1.86. The company has a 50 day moving average price of $3.76 and a 200-day moving average price of $3.43. Entero Therapeutics has a fifty-two week low of $1.87 and a fifty-two week high of $6.93.

Hedge Funds Weigh In On Entero Therapeutics

An institutional investor recently bought a new position in Entero Therapeutics stock. DRW Securities LLC acquired a new stake in Entero Therapeutics, Inc. (NASDAQ:GRDX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned approximately 1.45% of Entero Therapeutics at the end of the most recent reporting period. Institutional investors own 12.30% of the company’s stock.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.